Tyr3-Octreotate
Rapid kit-based 68Ga-labelling and PET imaging with THP-Tyr3-octreotate: a preliminary comparison with DOTA-Tyr3-octreotate
... THP-TATE was radiolabelled with 68 Ga 3+ from a 68 Ge/ 68 Ga generator. In vitro uptake was assessed in SSTR2- positive 427-7 cells and SSTR2-negative 427 (parental) cells. Biodistribution of [ 68 Ga(THP-TATE)] was ...
11
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
... When 177 Lu-DOTATATE was administered 4 days after RAD001 therapy, however, there was no reduction in the percentage of rats developing metastases in the combination therapy groups, indi[r] ...
10
Ilhan, Harun (2013): Evaluierung neuer nephroprotektiver Strategien in einem Mausmodell der strahleninduzierten Nephropathie durch den ß-Emitter [Lu-177-DOTA0,TYR3]-octreotate mittels in-vivo Tc-99m-MAG3 Nierenfunktionsszintigraphie. Dissertation, LMU München: Medizinische Fakultät
... Die strahleninduzierte Nephropathie stellt neben der Hämatotoxizität den Dosis- und Therapie-limitierenden Faktor im Rahmen der Peptid-Rezeptor- Radionuklid-Therapie (PRRT) dar. Die PRRT ist eine nuklearmedizinische ...
65
Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
... acquired at a later time point. Regarding the three im- aging time points 24, 48, and 72 h, which were available for this study, the time points of 48 or 72 h p. i. were found to be suitable for Lu-177-PSMA-617 therapy. ...
16
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice
... through a reverse polyploidy pathway that may be acti- vated by the self-renewal stem cell genes, NANOG, OCT4, and SOX2 [49]. Despite the extensive effects of 177 Lu-DOTA-Tyr 3 -octreotate treatment observed after ...
13
Evaluation and comparison of different quality control methods in radiochemical purity determination of new peptide kits 99mTc-EDDA-Tricine-HYNIC-Tyr3-Octreotide and 99mTc-EDDA-Tricine-HYNIC-Tyr3-Octreotate for imaging somatostatin receptor positive tumors [Persian]
... ﺎﻫ ﻪﺘﻓﺎﻳ : زا هدﺎﻔﺘﺳا ﻪﭼﺮﮔا ،ﺪﻨﺘﺷاد ار هﺪﺷ ﺮﻛذ يﺪﻴﺘﭙﭘ يﺎﻫ ﺖﻴﻛ ﻲﻳﺎﻴﻤﻴﺷﻮﻳدار صﻮﻠﺧ ﻦﻴﻴﻌﺗ ياﺮﺑ مزﻻ ﻲﻳآرﺎﻛ شور ﻪﺳ ﺮﻫ HPLC.. ﺮﺗ ﻖﻴﻗد و.[r] ...
7
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
... Peptide receptor radionuclide therapy (PRRT) is an ef- fective treatment option for patients with an inoperable neuroendocrine tumour (NET) or with metastatic dis- ease [1, 2]. Approximately 80 % of patients with NET ...
10
Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model
... somatostatin analogs, all imaging and distribution studies similarly showed significantly reduced radiotracer uptake in tumors (Figure 3 D-F) in the order of [ nat [r] ...
16
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
... The liver, spleen, kidneys, and red marrow dose per administered activity (AD/A admin) values were calculated with the Medical Internal Radiation Dose (MIRD) formalism and the residence [r] ...
13
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
... In the mid-2000s, another radiopharmaceutical, 177Lu- DOTA-Tyr3-octreotate (177Lu-Dotatate), was synthesized. The lower tissue penetration of 177Lutetium (Emax 0:49 MeV, Rmax 2 mm) is balanced by a longer ...
7
Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with 177Lu-octreotate
... Lu-octreotate treatment in humans. It should be noted that urinary RBP4 level only indicates impairment of prox- imal tubular cells and may not reflect effects on the other parts of the kidney. Before RBP can be ...
9
Comparing diagnostic performance of 131I-metaiodobenzylguanidine (131I-MIBG) and 99mTc-hydrazinonicotinyl-Tyr3-Octreotide (99mTc-HYNIC-TOC) in diagnosis and localization of pheochromocytoma and neuroblastoma
... Also, it seems that somatostatin receptor scintigraphy can be superior to MIBG concerning more cost-effectiveness, lower radiation dose to the patient, shorter required time for [r] ...
8
Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
... Lu-[DOTA 0 , Tyr 3 ]-octreotate ( 177 Lu-octreotate) is used to treat patients with somatostatin receptor (SSTR)-positive neuroendocrine (NE) tumors. The cure rate after 177 Lu-octreotate is high in ...
16
Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma
... Favourable outcomes of peptide receptor radiotherapy (PRRT) of neuroendocrine tumours have been reported during the last years. Still, there are uncertainties on the radionuclides to be used, the treatment planning, and ...
13
Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors
... Few studies have reported the possible positive effects associated with the presence of high peptide amounts on the uptake of radiolabeled somatostatin analogues in tumor tissues [28,30-32]. A systematic investigation of ...
6
[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
... In progressive low- and intermedi- ate-grade GEP-NET patients, a PFS of 34.5 months and a high tumour control rate (objective response 54.2%, stable disease 45.8%) indicate that 177 [r] ...
10
Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy
... Dosimetric estimations for patients treated with 177 Lu- octreotate have previously been published [15,17-20]. Results from these publications demonstrate variations in absorbed dose to the kidneys between clinics ...
13
Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
... Results: RNA microarray analysis was performed on tumor samples from GOT1-bearing BALB/c nude mice treated with a 5 MBq priming injection of 177 Lu-octreotate followed by a second injection of 10 MBq of 177 ...
11
Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
... Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of surgical cure. Several treatment options have been used in experimental ...
5